Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-04-26
2005-04-26
Li, Q. Janice (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000, C424S093100, C536S023100
Reexamination Certificate
active
06884786
ABSTRACT:
Antitumoral compositions can comprise as therapeutic agent one or several immunogenic polypeptides, of which at least one is modified so as to have a cell location different from its native location. Compositions can be based on a recombinant vector expressing such an immunogenic polypeptide. A recombinant vector comprising at least the sequences coding for an immunogenic polypeptide originating from a precocious and/or tardive region of a papillomavirus having a modified location and a viral particle comprising the vector is also described. Finally, therapeutic uses of such a composition, such a recombinant vector and such a viral particle are described.
REFERENCES:
patent: 5185146 (1993-02-01), Altenburger
patent: 5348867 (1994-09-01), Georgiou et al.
patent: 5958736 (1999-09-01), Sthl et al.
patent: 6096869 (2000-08-01), Stanley et al.
patent: 83 286 (1983-07-01), None
patent: 206 920 (1986-12-01), None
patent: 0 305 229 (1989-03-01), None
patent: 2583429 (1986-12-01), None
patent: 85 09480 (1986-12-01), None
patent: 94 08300 (1996-01-01), None
patent: 97 05203 (1998-10-01), None
patent: 87 06260 (1987-10-01), None
patent: 87 07642 (1987-12-01), None
patent: 90 10459 (1990-09-01), None
patent: 93 00436 (1993-01-01), None
patent: 9302184 (1993-02-01), None
patent: 94 21680 (1994-09-01), None
patent: 9428152 (1994-12-01), None
patent: 9617070 (1996-06-01), None
patent: 96 39178 (1996-12-01), None
patent: 9704119 (1997-02-01), None
patent: 97 27216 (1997-06-01), None
Andrew et al, J Virol 1990;64:4776-83.*
Boursnell et al, Vaccine 1996;14:1485-94.*
Borysiewicz et al, Lancet 1996 Jun;347:1523-7.*
Sutter et al, Vaccine 1994;12:1032-40.*
Genome database for HPV E6, NCBI. 2004.*
Chemical compound Britannica Encylopedia 1994-2000.*
Bowie et al. deciphering the message in protein sequences: tolerance to amino acid substitutions vol. 247 pp. 1306-13101990.*
Bork Powers and pitfalls in sequence ananlysis: The 70% hurdle pp. 398-400 2000.*
Scott et al. The pendred syndrome gene encodes a chloride-iodide transport protein pp. 440-443 vol. 21 1999.*
Everett et al. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS) pp. 411-421 1997.*
Rudinger Characteristics of the amino acids as components of a peptide hormone sequence pp. 1-7 1976.*
GF Arnold et al., Virology, “Design and Construction of Rhinovirus Chimeras Incorporating Immunogens from Polio, Influenza, and Human Immunodeficiency Viruses,” 1994, 198, pp. 703-708.*
B Bodey et al., Anticancer Research, “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy,” 2000, 20:2665-2676.*
S Radoja et al., Molecular Medicine, “Cancer-induced Defective Cytotoxic T Lymphocyte Effector Function: Another Mechanism How Antigenic Tumors Escape Immune-mediated Killing,” 2000, 6(6):465-479.*
Lin et al., Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen, 1996, Cancer Research, vol. 56, pp. 21-26.*
Boursnell et al., Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer, 1996, VACCINE, vol. 14, pp. 1485-1494.*
Jarrett et al., Studies on vaccination against papillomaviruses: Prophylactic and therapeutic vaccination with recombinant structural proteins, 1991, VIROLOGY, vol. 184, pp. 33-42.*
He et al., Construction of adenoviral and retroviral vectors coexpressing the genes encoding the hepatitis B surface antigen and B7-1 protein, 1996, GENE, vol. 175, pp. 121-125.*
Chow et al., Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2, 1997, Journal of Virology, pp. 169-178.*
McCluskie et al., Route and method of delivery of DNA vaccine influenza immune responses in mice and non-human primates, 1999, Molecular Medicine, vol. 5, pp. 287-300.*
Gupta et al., Identification of novel transmembrane gene sequence and its use for cell-surface targeting of BETA subunit of human chorionic gonadotropin, 1998, DNA and Cell Biology, vol. 17, pp. 573-581.*
Kim et al., In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with DNA immunogen, 1997, Journal of Immunolgy, pp. 816-826.*
Finke et al., Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with interleukin-7 gene, 1998, Gene Therapy, vol. 5, pp. 31-39.*
Deonarain, Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patent, vol. 8, pp. 53-69.*
Verma et al., Gene therapy-promises, problems and prospects, 1997, NATURE, vol. 389, pp. 239-242.*
Crystal, Transfer of gene to humans: Early lessons and obstacles to success, 1995, SCIENCE, vol. 270, pp. 404-410.*
Miller et al., Targetd vetors for gene therapy, 1995, FASEB J., vol. 9, pp. 190-199.*
Yang et al. Journal of Biological Chemistry 272(3):1970-1975, Jan. 1997.*
Boursnell M. et al, “Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer” VACCINE, vol. 14, No. 16, 1996, pp. 1485-1494. XP002061738.
Meneguzzi G. et al, “Vaccination Against Papillomavirus-Induced Tumors Using Vacinia Recombinants Expressing Non-Structural Proteins”, Journal of Cellular Biochemistry, No. SUP. 13, Part C, Jan. 1, 1989, p. 210 XP000121130.
Jarrett W.F.H. et al, “Studies On Vaccination Against Papillomaviruses: Prophylactic and Therapeutic Vaccination With Recombinant Structural Proteins”, Nucleic Acids Research, vol. 184, 1991, pp. 33042, XP002023588.
Seedorf K. et al., “Human Papillonmavirus Type 16 DNA Sequence”, Virology, vol. 145, No. 1, Aug. 1985, pp. 181-185, XP002059799.
Pfister, 1987, inThe papovaviridae: The Papillomavirus, Salzman and Howley edition, Plenum Press, New York, p. 1-38.
Schlaegel et al, 1986, Science 233, 464-467.
Kanda et al, 1988, J. Virol. 62, 610-613.
Vousden et al, 1988, Oncogene Res. 3, 1-9.
Bedell et al, 1987, J. Virol. 61, 3635-3640.
Munger et al, 1989, EMBO J. 8, 4099-4105.
Heck et al, 1992, Proc. Natl. Acad. Sci. USA 89, 4442-4446.
Crook et al, 1991, Cell 67, 547-556.
Miki et al, 1994, Science 226, 66-71.
Wooster et al, 1995, Nature 378, 789-792.
Hareuveni et al, 1990, Proc. Natl. Acad. Sci. USA 87, 9498-9502.
Branden and Tooze, 1991, Introduction to Protein Structure, p. 202-214, NY, Garland.
Zhou et al, 1991, Virology 185, 625-632.
Tobery and Siliciano, 1997, J. Exp. Med. 5, 909-920.
Kaisho et al, 1997, Science 276, 412-414.
Mochamer and Rose, 1987, J. Cell. Biol. 105, 1205-1214.
Mochamer, 1993, Curr. Opin. Cell Biol. 5, 606-612.
Ensinger et al, 1972, J. Virol. 10, 328-339.
Ketner et al, 1989, Nucleic Acids Res. 17, 3037-3048.
Gooding et al, 1990, Critical Review of Immunology, 10, 53-71.
Freeman et al, 1989, J. of Immunology 143, 2714-2722.
Taniguchi et al, 1983, Nature 302, 305-311.
Phelps et al, 1992, J. Virol. 66, 2418-2427.
Graham and Prevect, 1991, Methods in Molecular Biology, vol. 7, p. 109-128.
Naviaux and Verma, 1992, Current Opinion in Biotechnolgy 3, 540-547.
Meyer et al, 1991, J. Gen. Virol. 72, 1031-1038.
Sutter et al, 1994, Vaccine 12, 1032-1040.
Chen et al, 1995, J. Clin. Invest. 96, 2775-2782.
Vile et al, 1993, Cancer Res. 53, 3860-3864.
Harris et al, 1994, Gene Therapy 1, 170-175.
Chakrabarti et al, 1997, Biotechniques 23, 1094-1097.
Hammond et al, 1997, J. Virological Methods 66, 135-138.
Kumar and Boyle, 1990, Virology 179, 151-158.
Felgner et al, 1989, Proc. West. Pharmacol. Soc. 32, 115-121.
Hodgson and Solaiman, 1996, Nature Biotechnology 14, 339-342.
Remy et al, 1994, Bioconjugate Chemistry 5, 647-654.
Lynch et al, 1997, Nature Medicine 3, 625.
Brasel et al, 1996, Blood 88, 2004-2012.
Marakovsky et al, 1996, J. Exp. Med. 184, 1953-1962.
Graham et al, 1977, J. Gen. Virol. 36, 59-72.
Imler et al, 1996, Gene Therapy 3, 75-84.
Yeh et al, 1996, J. Virol. 70, 559-565.
Krougliak
Balloul Jean-Marc
Bizouarne Nadine
Kieny Marie-Paule
Burns Doane Swecker & Mathis L.L.P.
Li Q. Janice
Transgene S.A.
LandOfFree
Antitumoral composition based on immunogenic polypeptide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antitumoral composition based on immunogenic polypeptide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumoral composition based on immunogenic polypeptide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387239